Teva Migraine Drug Wins FDA Nod, Bolstering Turnaround Plan

(Bloomberg) -- Teva Pharmaceutical Industries Ltd. won U.S. regulatory approval to sell a new treatment for migraines, a key part of the company’s turnaround strategy. The stock surged in after-hou...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.